NCT03708328View on ClinicalTrials.gov

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

July 9, 2024

Study Completion Date

July 9, 2024

Conditions
Solid TumorsMetastatic MelanomaNon-small Cell Lung Cancer (NSCLC)Small Cell Lung Cancer (SCLC)Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
DRUG

Lomvastomig

Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.

Trial Locations (17)

1023

Auckland City Hospital, Auckland

2100

Rigshospitalet, København Ø

2730

Herlev Hospital, Herlev

10032

Columbia Univ Med Ctr, New York

13005

CHU Timone, Marseille

28034

Hospital Ramon y Cajal, Madrid

28040

START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid

31008

Clinica Universitaria de Navarra, Pamplona

33076

Institut Bergonie, Bordeaux

44805

ICO Rene Gauducheau, Saint-Herblain

46010

Hospital Clínico Universitario de Valencia, Valencia

69008

Centre Leon Berard, Lyon

77030

MD Anderson Cancer Center, Houston

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

08035

Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03708328 - A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter